Short Activity in PNV, page-6215

Frustrating is the word. Having listened to the results webcast, it is clear that growth will continue in current markets, in new countries and in new clinical areas. We are well on the way, if not already in some areas, the standard of care for dermal replacement in burns, trauma, diabetic foot ulcers, and now trauma. The addressable market continues to grow with cancer surgery being a notable recent area with increasing case reports.
The sharemarket is clearly risk off in the current economic environment and non profitable biotechs are out of favour with valuations at historic lows. However, we are cashed up and DW stated “no cap raises in the foreseeable future”. Our markets/business are essentially recession proof and if anything should have increased uptake if health services are squeezed financially - being cheaper and reducing length of stay and operating time cf alternatives such as full flap grafts, as DW commented in the webcast.
Whether we need to drop out of the ASX 200 to shake the shortsellers (rebalance due in September and what other motivation could they have) or wait for a fundamental catalyst (sales, BARDA, Japan etc), I am confident the reversal will come sooner or later and the share price will more accurately reflect the fundamentals. The future looks bright IMO and those with patience and intestinal fortitude will be well rewarded.